Bicalutamide (Casodex, Cosudex, Calutide, Kalumid) is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism. It was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease.
Bicalutamide is an oral non-steroidal anti-androgen with the empirical formula C18H14F4N2O4S and is an off-white powder that is practically insoluble in water.
Bicalutamide acts as a pure anti-androgen by binding to the androgen receptor (AR) and preventing the activation of the AR and subsequent upregulation of androgen responsive genes by androgenic hormones. In addition, bicalutamide accelerates the degradation of the androgen receptor. Bicalutamide has been used as a molecular template for the design of selective androgen receptor modulators (SARMs) such as Andarine and Ostarine.
Indications and use
Bicalutamide is indicated for the treatment of stage D2 metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone analogue or as a monotherapy. It has also been used in clinical trials for ovarian cancer. It has also been used in combination with castration.
Most advanced prostate cancer patients eventually become resistant to antiandrogen including bicalutamide therapy.
Bicalutamide is contraindicated in patients who have shown a hypersensitivity reaction to its use. Bicalutamide is a teratogen and must not be handled by females who are or may become pregnant. It is known to cause fetal harm. pg8
Caution is required when used together with other medications that depend on CYP3A4 and CYP2D6 metabolisation.
Bicalutamide blocks androgen receptors. This prevents testosterone and other androgens from binding to the receptors. Bicalutamide may cause sexual difficulties and a decline in sperm count. Nevertheless bicalutamide monotherapy appears to have minimal effect on sexual activity.
Blockade of androgen receptors by bicalutamide in the brain will eliminate the negative feedback loop of testosterone on the release of luteinizing hormone (LH). This in turn will lead to a dramatic increase in testosterone and estrogen levels. Bicalutamide treatment will block the effects of rising testosterone levels, but the effect of rising estrogen levels will remain unopposed and lead to feminizing effects, the most notable one being gynecomastia, which is often painful.
If bicalutamide is combined with a GnRH agonist or surgical castration then the elevation of estrogen levels will be prevented and the risks of excessive estrogen will be reduced. However, since both testosterone and estrogens are essential for normal bone metabolism, reducing the anabolic bone effects of both androgens (which increase bone formation by stimulating osteoblasts) and estrogens (which reduce bone resorption by inhibiting osteoclasts) will increase bone loss and promote osteoporosis.
^See WA, Tyrrell CJ (August 2006). "The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer". Journal of cancer research and clinical oncology. 132 Suppl 1: S7–16. doi:10.1007/s00432-006-0132-6. PMID16896884.
^Müderris II, Bayram F, Ozçelik B, Güven M (February 2002). "New alternative treatment in hirsutism: bicalutamide 25 mg/day". Gynecol. Endocrinol.16 (1): 63–6. doi:10.1080/713602986. PMID11915584.
^Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ (September 1997). "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group". Urology50 (3): 330–6. doi:10.1016/S0090-4295(97)00279-3. PMID9301693.
^Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P (December 2007). "A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission". Cancer110 (11): 2448–56. doi:10.1002/cncr.23072. PMID17918264.
^Mason M (August 2006). "What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?". J. Cancer Res. Clin. Oncol. 132 Suppl 1: S27–35. doi:10.1007/s00432-006-0134-4. PMID16896883.
^Eri LM, Haug E, Tveter KJ (March 1995). "Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia". Br J Urol75 (3): 335–40. doi:10.1111/j.1464-410X.1995.tb07345.x. PMID7537602.
^Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ (March 1989). "Androgens directly stimulate proliferation of bone cells in vitro". Endocrinology124 (3): 1576–8. doi:10.1210/endo-124-3-1576. PMID2521824.
^Manolagas SC, Jilka RL, Girasole G, Passeri G, Bellido T (1993). "Estrogen, cytokines, and the control of osteoclast formation and bone resorption in vitro and in vivo". Osteoporosis International. 3 Suppl 1: 114–6. doi:10.1007/BF01621882. PMID8461536.
^Tucker, H.; Crook, J. W.; Chesterson, G. J. (1988). "Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides". Journal of Medicinal Chemistry31 (5): 954. doi:10.1021/jm00400a011.edit